Bexarotene: A Rare Cause of Misleading Thyroid Function Tests

Vishwanath Pattan 1, Kira Schaab 2, Vishnu Sundaresh 3

1. Endocrinology, Wyoming Medical Center, Casper, USA 2. Family Medicine, The University of Wyoming Family Medicine Residency Program-Casper, Casper, USA 3. Endocrinology, University of Utah Health, Salt Lake City, USA

Corresponding author: Vishwanath Pattan, vpattan@wyomingmedicalcenter.org

Abstract
Bexarotene is a very rare cause of central hypothyroidism (CH) and its effects have been reported to be dose-dependent; however, the available data in the literature on dose-dependent effects are variable. The standard practice of monitoring thyroid function using thyroid-stimulating hormone (TSH) to adjust levothyroxine (LT4) dose does not apply to bexarotene since it causes CH. In CH, TSH is not reliable. Hence free tetraiodothyronine (fT4) level is used to monitor and adjust the LT4 dose. We report a case of an 81-year-old Caucasian male with cutaneous T-cell lymphoma (CTCL) who was treated with bexarotene. His pre-treatment TSH was normal at 1.6 µU/mL (reference range: 0.46-4.68 µU/mL). Post-bexarotene, the total triiodothyronine (T3) level was within the reference range, but a downward trend was noted. Eventually, total triiodothyronine (T3) dropped to a low level of 0.61 ng/mL (reference range: 0.97-1.69 ng/mL), and LT4 was initiated. Bexarotene dose was increased, but LT4 was not increased by the primary physician who relied on TSH level, which was low, and hence the existing LT4 dose was maintained. The patient had persistent symptoms of hypothyroidism, and eventually, a diagnosis of CH was made. The symptoms of hypothyroidism improved after normalizing fT4, with an increase in the LT4 dose. This case represents an example of missed CH due to bexarotene, which led to suboptimal LT4 replacement impacting the quality of life for the patient.

Categories: Endocrinology/Diabetes/Metabolism
Keywords: central hypothyroidism, bexarotene, mycosis fungoides, cutaneous T-cell lymphoma

Introduction
The standard practice in the management of primary hypothyroidism involves monitoring of thyroid-stimulating hormone (TSH) to guide dose adjustments for levothyroxine (LT4). However, an exception to this is central hypothyroidism (CH), which is caused mostly by pituitary tumor/surgery and drugs. In this situation, TSH is unreliable and hence free tetraiodothyronine (fT4) is used for monitoring and adjusting the LT4 dose. The goal set for fT4 is just above the 50th percentile of the normal reference range (0.8-2.19 ng/dL) to achieve a good quality of life. Recognizing the drugs that can cause CH and changing the practice of hypothyroidism management accordingly are important to prevent therapeutic mishaps. Bexarotene is a synthetic retinoid, which selectively activates the retinoid X receptor [1]. Bexarotene is a rare but well-recognized cause of CH, and it has been reported to cause dose-dependent suppression of TSH [2]. In the last decade, several new drugs have been reported to cause CH, and providing continuing medical education to primary care physicians is very important. In this case report, we discuss the challenges of diagnosing and managing bexarotene-induced CH in the primary care setting.

Case Presentation
An 81-year-old Caucasian male presented to the endocrinology office for the management of hypothyroidism in February 2020. The patient had initially presented in 2014 with a rash on the left palm and wrist (Figure 1) and right thigh. He had undergone a biopsy and had been diagnosed with cutaneous T-cell lymphoma (CTCL) (mycosis fungoides). He had been started on bexarotene 150 mg (two tablets of 75 mg each) daily in August 2015, and the dose had been temporarily increased to 500 mg (two tablets of 75 mg each) daily during disease exacerbation. Bexarotene had been tapered down to 150 mg per day whenever the flares had resolved. His baseline TSH had been 1.6 µU/mL (reference range: 0.46-4.68 µU/mL). He had follow-up labs ordered for total tetraiodothyronine or total T4 by the oncologist, which had been normal until March 2016 but showed a downward trend. In April 2016, total triiodothyronine or total T3 had been low at 0.61 ng/mL (reference range: 0.97-1.69 ng/mL), and LT4 50 µg daily had been initiated by the oncologist (Table 1). Subsequently, the patient had been followed up by the primary care physician for the management of hypothyroidism.

How to cite this article
Pattan V, Schaab K, Sundaresh V (November 20, 2020) Bexarotene: A Rare Cause of Misleading Thyroid Function Tests. Cureus 12(11): e11591.
DOI 10.7759/cureus.11591
Lab reviews had revealed that the T₄ or fT₄ decreased when the dose of bexarotene was increased (all available labs are summarized in Table 1). Conversely, the T₄ or fT₄ levels increased when bexarotene was decreased or stopped. The patient had been maintained on LT4 50 µg daily until March 2017 when both bexarotene and LT4 had been held during the hospitalization for sepsis due to pneumonia. This discontinuation had normalized the fT₄ levels to 1.13 ng/dL in March, and to 1.3 ng/dL in April 2017. Although bexarotene had been restarted after three weeks in April 2017, LT4 had not been restarted until May 2017. By May 2017, fT₄ had dropped to 0.5 ng/dL and LT4 75 mcg was restarted. The patient had persistently low T₄, fT₄, and T₃ values, but LT4 had not been increased beyond 75 µg daily, because of concerns related to suppressed TSH.

| Date       | Free T₃ (reference range: 2.77-5.27 pg/mL) | Total T₃ (reference range: 0.97-1.69 ng/mL) | Free T₄ (reference range: 0.8-2.19 ng/dL) | Total T₄ (reference range: 5-12 µg/dL) | TSH (reference range: 0.46-4.68 µIU/mL) | Daily bexarotene dose (mg) | Levotyroxine dose (µg) |
|------------|------------------------------------------|-------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|---------------------------|--------------------------|
| 6/3/2014   |                                          |                                           |                                          | 1.60 (N)                                 |                                          |                           |                          |
| 2/3/2016   |                                          |                                           |                                           | 6.4 (N)                                  |                                          | 150 to 300                 |                          |
| 3/17/2016  |                                          | 5.3 (N)                                   |                                          |                                          |                                          |                           |                          |
| 4/15/2016  | 0.61 (L)                                 |                                           |                                          |                                           |                                          |                           |                          |
| 7/11/2016  | 0.89 (L)                                 | 7.9 (N)                                   |                                          |                                          |                                          |                           |                          |
| 8/1/2016   | 3.28 (N)                                 | 7.7 (N)                                   |                                          |                                          |                                          |                           |                          |
| 9/9/2016   | 2.66 (L)                                 |                                           | 1.14 (N)                                 |                                          |                                          | 300                       | 50                       |
| 10/5/2016  | 0.57 (L)                                 |                                           | 6.0 (N)                                  |                                          |                                          | 300                       | 50                       |
| 11/7/2016  | 0.874 (L)                                |                                           | 1.15 (N)                                 |                                          |                                          | 300                       | 50                       |
| 1/23/2017  | 1.01 (N)                                 |                                           | 8.2 (N)                                  |                                          |                                          | 300                       | 50                       |
| 3/7/2017   |                                           | 1.13 (N)                                 |                                          |                                           |                                          |                           |                          |
| 4/3/2017   |                                           |                                           | 1.30 (N)                                 |                                           |                                           |                           |                          |

stopped for 3 weeks
stopped

2020 Pattan et al. Cureus 12(11): e11591. DOI 10.7759/cureus.11591
The patient was initially seen by the endocrinologist in February 2020 because of a persistent abnormal thyroid function test. He was not using biotin and had not received iodinated contrast previously. Pertinent review of symptoms included decreased exercise tolerance, muscle aches and pain in the extremities, decreased appetite, cold intolerance, and easy bruising. On physical examination, the thyroid was normal in size, with no palpable nodules and no bruit on auscultation.

Additional labs were ordered for screening of pituitary hormonal function, which were normal: alpha subunit: 0.3 ng/mL (reference range: 0-0.4 ng/mL), prolactin: 12.5 pg/mL (reference range: 4-15.2 pg/mL), adrenocorticotropic hormone (ACTH): 22 pg/mL (reference range: 7.2-65 pg/mL), and cortisol: 14.8 µg/dL (reference range: 4.46-22.7 µg/dL). MRI brain/pituitary showed a normal sized pituitary gland without tumor or metastasis.

LT4 was increased to 100 µg daily in February 2020, and a repeat thyroid lab panel two weeks later showed fT4 of 0.6 and free T3 (fT3) of 1.36 (reference range: 2.27-5.27 pg/mL). The LT4 dose was increased to 112 µg daily and a thyroid lab panel was ordered every four weeks. Unfortunately, the patient missed his follow-up labs due to fear and restrictions due to coronavirus disease 2019 (COVID-19) pandemic. LT4 dose was eventually increased to 150 µg daily and then the fT4 was found normalized in the follow-up lab done three weeks later. The thyroid lab panel showed fT4 of 1.1 ng/dL and fT3 of 2.37 with undetectable TSH. The patient endorsed significant improvement in his energy levels with this change, and LT4 150 µg daily was

| Date       | fT4 (L) | free T3 (fT3) (L) | Dose (µg) | Notes                                      |
|------------|--------|-------------------|-----------|--------------------------------------------|
| 4/6/2017   | 0.82   | <0.015            | 300       | Stopped                                    |
| 5/4/2017   | 0.50   | 0.127             | 300       | 75 (restarted)                             |
| 5/23/2017  | 0.52   | 0.127             | 300       | 75                                         |
| 6/21/2017  | 1.94   | 0.127             | 300       | Decreased to 225 mg                         |
| 7/31/2017  | 2.62   | 0.127             | 225 mg    | 75                                         |
| 10/9/2017  | 2.49   | <0.015            | 300       | Increased to 375 mg in December for flare   |
| 1/2/2018   | 2.45   | 0.76              | 300       | 75                                         |
| 3/7/2018   | 2.67   | 0.83              | 300       | 75                                         |
| 4/30/2018  | 1.81   | 0.72              | 300       | 75                                         |
| 7/20/2018  | 2.89   | 0.81              | 375       | 75                                         |
| 9/14/2018  | 3.20   | 0.62              | 300       | 75                                         |
| 4/12/2019  | 2.21   | 0.77              | 300       | 75                                         |
| 8/20/2019  | 2.44   | 0.70              | 375       | 75                                         |
| 1/27/2020  | 2.25   | 0.59              | 450       | Increased from 75 to 100 on 2/18/2020       |
| 3/3/2020   | 2.01   | 0.60              | 450       | Increased from 100 to 112                   |
| 7/20/2020  | 1.36   | 0.7               | 0.089     | 450                                        |
| 8/10/2020  | 2.37   | 1.1 (N)           | <0.015    | 450                                        |

**TABLE 1: Serial thyroid lab panel and the corresponding doses of levothyroxine and bexarotene**

*(N): lab value is within the normal range; (L): lab value is below the normal range; TSH: thyroid-stimulating hormone; T3: triiodothyronine; T4: tetraiodothyronine*
continued. The goal was to slowly titrate the dose up further to bring fT$_4$ to the upper half of the reference range. Unfortunately, the patient passed away six weeks later due to acute myocardial infarction.

**Discussion**

Bexarotene is a synthetic retinoid, which selectively activates the retinoid X receptor and is used to treat CTCL. It has a peak plasma concentration two hours after ingestion and a half-life of seven hours [1]. Bexarotene selectively inhibits TSH secretion and can therefore lead to CH [2]. In vitro studies have shown that ligands for the retinoid X receptor suppressed the activity of thyrotropin β-subunit gene promoter [3,4]. The decrease in TSH concentrations was reported to be greater in patients who had received higher doses of bexarotene [2]. In phase II and phase III clinical trials in the United States, Duvic et al. (2001) reported that 30-40% of patients exhibited hypothyroidism at a bexarotene dose of 300 mg/m$^2$/day, and approximately 50% of patients exhibited this outcome at doses of more than 300 mg/m$^2$/day (i.e., 500 or 650 mg/m$^2$/day) [5,6].

According to the United Kingdom consensus statement on safe clinical prescribing of bexarotene, TSH suppression of bexarotene is dose-dependent (Scarisbrick et al., 2013) [7]. Thus, preventive supplementation with LT4 may be appropriate when using bexarotene. It was recommended that LT4 be initiated from day one. LT4 can be started at a low dose of 25-50 µg daily and subsequently titrated to keep the fT$_4$ in the upper third of the reference range [7].

The data regarding the dose-dependent drop in TSH and fT$_4$ are not consistent. Makita et al. (2019) studied 66 Japanese patients with CTCL on bexarotene [8]. They did not find any dose-dependent effects on TSH and fT$_4$ in the dose range of 96-320 mg/m$^2$/day. Thus, the dose range of bexarotene and patient ethnicity may influence these effects.

In our patient, the suppression of TSH was observed when increasing the LT4 dose, which was misleading to primary care providers. Earlier detection of the etiology of the patient’s CH may have resulted in more appropriate dose adjustments leading to improved symptoms and better quality of life.

It is important to recognize that changes in bexarotene dose may influence the LT4 dose. LT4 dose requirement may increase with an increase in bexarotene dose. Likewise, the LT4 dose requirement may decrease with a decrease in bexarotene dose or with its discontinuation. Therefore, frequent monitoring of thyroid lab panels and knowledge about changes in bexarotene dose are important. Familiarity and early recognition of bexarotene-induced CH with both TSH and fT$_4$ testing can lead to early diagnosis and management of the condition, thereby improving treatment outcomes for the patient.

**Conclusions**

Bexarotene causes CH and the effect seems to be dose-dependent. Preventive supplementation with LT4 may be appropriate when using bexarotene. Recognizing the drugs that can cause CH and changing the practice of hypothyroidism management to include a complete thyroid lab panel accordingly are critical to prevent therapeutic mishaps.

**Additional Information**

**Disclosures**

**Human subjects:** Consent was obtained by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** Vishnu Sundaresh has received payment from a patient education research grant from Radius Health Inc; however, it is not related to this manuscript and presents no conflict of interest with the presented case report. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

**References**

1. Panchal MR, Scarisbrick JJ: The utility of bexarotene in mycosis fungoides and Sézary syndrome. Onco Targets Ther. 2015, 8:367-373. 10.2147/OTT.S61308
2. Sherman SI, Gopal J, Haugen BR, Chiu AC, Whaley K, Nowlakha P, Duvic M: Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med. 1999, 340:1075-1079. 10.1056/NEJM199904083401404
3. Haugen BR, Brown NS, Wood WM, Gordon DF, Ridgway EC: The thyrotroph-restricted isoform of the retinoid X receptor-gamma 1 mediates 9-cis-retinoic acid suppression of thyrotropin-beta promoter activity. Mol Endocrinol. 1997, 11:481-489. 10.1210/molend.11.4.9905
4. Breen JJ, Hickok NJ, Gurr JA: The rat TSHbeta gene contains distinct response elements for regulation by
5. Duvic M, Martin AG, Kim Y, et al.: Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol. 2001, 137:581-585.

6. Duvic M, Hymes K, Heald P, et al.: Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol. 2001, 19:2456-2471. 10.1200/JCO.2001.19.9.2456

7. Sc arishbrick J, Morris S, Azurdia R, et al.: U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. Br J Dermatol. 2013, 168:192-200. 10.1111/bjd.12042

8. Makita N, Manaka K, Sato J, Mitani K, Nangaku M, Iiri T: Bexarotene-induced hypothyroidism: characteristics and therapeutic strategies. Clin Endocrinol (Oxf). 2019, 91:195-200. 10.1111/cen.13975